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Simvastatln therapy for hypercholesterolemic patients with nephrotic
syndrome or significant proteinurla. Experimental evidence suggests
that lipid lowering therapy could slow the progression of renal disease
in humans. We have conducted a double-blind, placebo controlled trial
of the HMG CoA reductase inhibitor simvastatin in patients with the
nephrotic syndrome or significant proteinuria (> I g/day) and hyper-
cholesterolemia ( 6.5 mmot/liter). Patients were placed on a lipid
lowering diet for at least 10 weeks before randomization. After a four-
week placebo run-in, 30 adults were randomized to simvastatin or
placebo therapy (10 mg/day, increasing to 20 to 40 mg/day as required)
for 24 weeks. There were seven dropouts, none of whom were
"definitely" related to drug therapy. Total and LDL cholesterol levels
fell by a mean of 33 and 31%, respectively, in simvastatin treated
patients, compared with only 5 and 1% in patients on placebo (P <
0.001, P = 0.002, respectively). Apolipoprotein Bl00 levels fell by a
mean of 31% in the simvastatin group but rose 0.3% in the placebo
group (P = 0.014). There were no significant changes in HDL levels.
There were no significant differences between the groups in their urine
protein levels, their rise in plasma creatinine, or decline in plasma inulin
clearance. Simvastatin is a safe, effective therapy for hypercholester-
olemia in proteinuric states. A much larger trial is needed to show if
potent lipid-lowering therapy slows progression of hypercholester-
olemic proteinuric diseases.
The hyperlipideniia of the nephrotic syndrome is character-
ized by elevated total and low density lipoprotein (LDL)
cholesterol [1, 2], with a rise in triglycerides and very low
density lipoprotein (VLDL) cholesterol most often seen in
patients with heavy proteinuria. Whether there are consistent
changes in high density lipoprotein (HDL) cholesterol levels in
the nephrotic syndrome remains uncertain [1, 21.
The causes of the altered lipoprotein levels are controversial.
There is evidence of increased LDL production in nephrotics
[2, 3], which may be more marked in those with heavier
proteinuria [41. There is also evidence of impaired receptor-
mediated clearance of LDL [4] and reduced catabolism of
VLDL in the VLDL-IDL (intermediate density lipoprotein)-
LDL cascade [5].
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The hyperlipidemia of proteinuric glomerular disease could
have two major adverse consequences. Firstly, it could con-
tribute to the increased risk of coronary heart disease seen in
nephrotics [6], and secondly it could hasten the progression of
renal failure [7]. Hence, there has recently been much interest
in the use of lipid lowering therapy in hyperlipidemic patients
with proteinuric glomerular disease.
Studies of lipid lowering therapy have been hampered by the
lack of potent agents which safely reduce the marked hyper-
cholesterolemia seen in the nephrotic syndrome. The advent of
the hydroxymethylglutaryl CoA (HMG CoA) reductase inhibi-
tors has provided an important new therapeutic option in the
treatment of hyperlipidemia [8]. They are competitive inhibitors
of HMG CoA reductase, the enzyme catalyzing the rate limiting
step in cholesterol biosynthesis. In the hepatocyte a reduced
intracellular pool of cholesterol leads to increased expression of
cell surface LDL receptors, and a fall in plasma LDL levels.
We have conducted a randomized, double-blind, placebo
controlled study of the use of the HMG CoA reductase inhibitor
simvastatin to treat hypercholesterolemia in patients with the
nephrotic syndrome or significant proteinuria. We aimed to
study the safety, efficacy and effects on renal function of
simvastatin compared to placebo in these patients over a six
month period.
Methods
Patients were eligible for the trial if they had significant
proteinuria (1 to 3.5 g/day) or the nephrotic syndrome (> 3.5
g/day), fasting cholesterol of 6.5 mmollliter or more after
dietary therapy, and were aged 18 to 70 years. All patients gave
informed consent for participation in the trial, which was
approved by the ethical committee at each center. The major
exclusion criteria for the trial were as follows: diabetes mellitus;
hypertriglyceridemia warranting drug therapy; end-stage renal
disease (requiring renal replacement therapy or likely to require
such during the trial); steroid-responsive minimal change dis-
ease; uncontrolled hypertension; impaired liver function (any
liver function test > 20% above upper limit of normal) or
history of hepatobiliary disease; recent myocardial infarction,
coronary artery bypass or unstable angina; women who were
1124
Fig. 1. Trial design. Drug dosage adjustments
shown were those for typical patients on
simvastatin or placebo.
pregnant, nursing, or not adequately protected against preg-
nancy; other lipid lowering or cyclosporine therapy; carcinoma,
lymphoma or amyloidosis.
The trial design is shown in Figure 1. Patients who met the
entry criteria were commenced (between weeks —16 and —10)
on a lipid lowering diet and all lipid lowering drugs were
discontinued. The diet was similar to the Step 1 diets of the
American Heart Association and the US National Cholesterol
Education Program [9]. It restricted total fat intake to 30% of
calories, divided equally between saturated, monounsaturated
and polyunsaturated fatty acids. Cholesterol intake was re-
stricted to 300 mg per day or less. Protein intake was not
changed at any stage, with patients typically consuming 1.0
g/kg/day. Patients were seen by a dietician at screening, weeks
—4,0 and 12. All patients underwent a four-week placebo run-in
during which they took placebo ("10 mg") with the evening
meal. Throughout the study patients were seen at four weekly
intervals after an overnight fast for examination, testing, and a
pill count to check compliance. At week 0 if patients again met
all the entry criteria they were randomized to either simvastatin
10 mg or placebo with the evening meal. Inulin clearance was
measured at weeks 0 and 24.
To achieve comparable levels of proteinuria in the active and
placebo groups, randomization was carried out with stratifica-
tion into high and low proteinuria groups. Those patients at
week —4 with proteinuria of 4 grams per day or more (the
estimated population median) were allocated to the high pro-
teinuria stratum. Drug dosage was adjusted from the week 4
visit onwards according to a fixed schedule, and the investigator
remained blind to the cholesterol level. The investigator was
advised by the laboratory on the correct dose (10, 20 or 40 mg,
simvastatin or placebo) to bring the total cholesterol level to 5.2
mmollliter or below.
Total cholesterol, triglycerides, lipoprotein subclasses (LDL,
VLDL, and HDL cholesterol), apolipoproteins B100 and A!,
and urine protein were measured by a single laboratory as
previously described [10]. Creatinine, liver function tests, and
creatine kinase levels were measured locally by autoanalyzer.
Plasma inulin clearance [11] was measured by giving a loading
dose of inulin (50 mg/kg), followed by an infusion (at a rate
calculated from creatinine clearance) to maintain the plasma
inulin level at 0.25 mg/mI. Specimens for steady-state plasma
inulin levels were taken at 80, 85 and 90 minutes after the
maintenance infusion was commenced. In our hands inulin
levels are in a steady state (they do not differ significantly) at 80
to 90 minutes (data not shown). Inulin was measured using a
resorcinol method as described [12]. Inulin clearance was
calculated per 1.73 m2 of body surface area, as the mean of
three separate measurements.
Statistical analysis examined the changes in each group from
the start of active therapy (week 0) to the end of the trial (week
24). Mean percentage (for lipoprotein levels) or absolute
changes (for other variables) for each group were compared by
a t-test. Triglyceride levels showed skewed distributions, and
median changes were compared with a Mann-Whitney U test.
The differences in percentage or absolute changes between
groups and their 95% confidence intervals (95% CI) were
calculated.
Results
Thirty patients from the three centers entered the study. At
randomization the two groups were broadly comparable (Table
1). Twenty-seven of the 30 patients had biopsy-proven glomer-
ular disease (Table 1). Renal function based on creatinine and
inulin clearance was similar in the two groups. Eighteen pa-
tients were in the high proteinuria stratum, twelve in the low
proteinuria stratum. Ten simvastatin treated patients and
eleven placebo treated patients took medications which had
potential effects on plasma lipoprotein levels (Table 1). In the
five patients on prednisolone the dose range was 2.5 to 15
mg/day (mean 6 mg/day). The five patients taking ACE inhibi-
tors were almost evenly split between the groups. Blood
pressure control was satisfactory during the trial in both groups.
Mean (SD) blood pressure values at the end of the trial were:
simvastatin group 141/81 (30/9); placebo group 140/86 (17/8) mm
Hg.
Twenty-three patients completed the trial. Seven patients did
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Simvastatin Placebo
N 15 15
Age (mean) years 52 49
Sex M/F 7/8 11/4
High/low 9/6 9/6
proteinuria stratum
Histological diagnoses
Membranous GN 9 6
FSGS 5 3
Othera 1 4
None — 2
Lipid active medications
Prednisolone 1 4
Loop diuretics 9 5
ACE inhibitors 2 3
Thiazides 1 0
Beta blockers 3 6
Clinical and laboratory variables at week 0
Mean (SD)
Blood pressure 136/78 (23/10) 138/85 (11/8)
mm Hg
Total cholesterol 9.16 (1.26) 9.46 (2.37)
mmol/liter
Triglycerides 3.10 (1.24) 2.76 (1.82)
mmo!/liter
Creatinine 139 (56) 150 (110)
wnol/!iter
Urine protein 5.92 (3.49) 4.40 (2.68)
g/24 hr
Inulin clearance 76.5 (36.5) 75.4 (40.2)
rn/f mmli .73 rn2
not complete the trial protocol, four of whom were on simvas-
tatin and three on placebo. Of those on simvastatin, one was
found at week 4 to have had elevated baseline aspartate
transaminase and creatine kinase values, and three had adverse
clinical events (gout, diarrhea, and atypical chest pain). Two
patients on placebo were unwilling to continue the trial and one
was withdrawn after developing a rash. Two patients on sim-
vastatin and one patient on placebo reported gastrointestinal
symptoms which were rated as possibly, probably or definitely
related to drug therapy. For most adverse events any relation to
drug therapy (simvastatin or placebo) was not clear. None of
these episodes (including those leading to patient withdrawal)
was rated as being "definitely" related to drug therapy.
Simvastatin (10 mg) produced a prompt mean fall of about
30% in both total and LDL cholesterol levels between weeks 0
and 4 (Fig. 2), while placebo treated patients showed a slight
rise in both these variables over that period. Nine of eleven
simvastatin patients were titrated up to 40 mg daily, while
eleven of twelve placebo patients were titrated up to 40 mg
daily. Titration of the simvastatin dosage produced a modest
further decline in total and LDL cholesterol levels. By week 24
total and LDL cholesterol levels had fallen by a mean of 33 and
31%, respectively, in simvastatin treated patients, compared
with mean falls of 5 and 1% in placebo treated patients. The
differences in mean percentage changes were —27% (95% CI
—38 to —17%) and —33% (95% CI —52 to —14%) for total and
LDL cholesterol, respectively. This difference in mean percent-
100
age change (weeks 0 to 24) was significant for total (P < 0.001)
and LDL cholesterol (P = 0.002).
Apolipoprotein (Apo) B 100 levels (Fig. 2) showed changes in
the treatment groups comparable to those seen in total and LDL
cholesterol. Both groups had mean Apo B 100 levels of 156
mgldl at randomization. In the simvastatin treated group Apo
B 100 levels showed a mean percentage drop of 31%, while in
placebo treated patients the mean percentage change was a rise
of 0.3%. The difference in mean percentage changes was —31%
(95% CI —53 to —9%). This difference between the two groups
in mean percentage changes in Apo B100 (week 0 to week 24)
was significant (P = 0.014).
At randomization median triglyceride values in both the
simvastatin and placebo treated groups were about 2.8 mmoll
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Fig. 2. Total (A) and LDL (B) cholesterol and apolipoprotemn BiOO (C)
levels in simvastatin (•) and placebo (0) groups. Values shown are
means with standard deviation bars.
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liter, They showed a downward trend during the trial, decreas-
ing by a median of 25% and 11%, respectively. The difference in
median percentage changes was —12% (95% CI —31 to 8%).
The difference in median percentage fall between groups was
not significant (P = 0.37). Mean VLDL cholesterol was about
1.7 mmollliter in both groups at randomization. In simvastatin
treated patients it decreased by a mean of 48%, compared with
a mean 3% decrease in patients who received placebo therapy.
The difference in mean percentage changes was —45% (95% CI
—78 to —11%). This difference was significant (P = 0.022).
Mean HDL cholesterol levels were comparable in both
groups, varying between 1.2 and 1.3 mmoLtliter from week —4
to week 24. HDL cholesterol fell by a mean of 1.6% in the
simvastatin treated patients, and rose by a mean of 2.2% in the
placebo treated group from week 0 to week 24. The difference
in mean percentage changes was —3.9% (95% CI —24% to
17%). This difference was not significant (P = 0.72).
Mean apolipoprotein Al levels rose from 129 mgldl (week 0)
to 144 mgldl (week 24) in simvastatin treated patients. In the
placebo group mean Apo Al levels fell from 142 mgldl to 133
mg/dl over the same period. However, the difference between
the groups in mean percentage changes (16%, 95% CI —8 to
41%) was not significant (P = 0.20).
The patients were stratified based on their urine protein
excretion at week —4 into high and low proteinuria groups for
randomization at week 0. Thus simvastatin and placebo treated
patients had similar mean urine protein excretion of 4.97 and
4.88 g/24 hr, respectively, at week —4. During the placebo
run-in phase (weeks —4 to 0), and to a much lesser extent during
the active treatment phase, the simvastatin treated group
showed a rise in proteinuria levels (Fig. 3). The placebo treated
group showed a slight fall in mean proteinuria levels, largely
due to remission of proteinuria in a single patient (data not
shown). Overall the mean change in proteinuria in each group
from week 0 to week 24 was small (0.2 g!24 hr and —0.5 g124 hr
in the simvastatin and placebo groups, respectively). The
difference in mean changes between the groups was 0.6 g/24 hr
(95% CI —1.6 to 2.9 g/24 hr), which was not significant (P =
0.56).
Creatinine values were slightly lower in simvastatin treated
patients at randomization compared with placebo treated pa-
tients (Table 1). By week 24 creatinine levels had increased by
a mean of 15.4 mol/liter in the simvastatin treated patients and
14.8 molIliter in placebo treated patients (difference in mean
changes 0.6 molIliter, 95% CI —23 to 25 pmolIliter, P = 0.96).
Inulin clearance (C1) in the two groups was similar both at
randomization (Table 1) and at the end of the trial. Mean C1,, fell
from 76.5 (N = 13) to 62.2 mllmin/1.73 m2 (N = 9) in the
simvastatin group and from 75.4 (N = 13) to 61.3 mllmin/1.73
m2 (N = 10) in the placebo group. There were no significant
differences between the groups with regard to mean inulin
clearances. Complete inulin clearance data were only available
in 17 patients, because of withdrawals, noncompliance and
24 technical failures. Inulin clearance tended to decrease at a
slower rate among simvastatin treated patients (mean change
—4.1, SD 25, median —5.0 mlIminIl.73 m2, N = 7) compared
with placebo treated patients (mean change —16.7, SD 21,
median —10.0 ml!minll.73 m2, N = 10). This difference was not
significant (P = 0.27, f-test). The point estimate of the differ-
ence in the C1 fall between groups was 12.5 mllminll .73 m2
(95% CI 36 to —11 mlIminIl.73 m2).
Discussion
Hyperlipidemia is a frequent complication of the nephrotic
syndrome [13], but its importance has been unclear. The
relationship of nephrotic syndrome to coronary heart disease is
controversial [14, 15]. It may itself accelerate the progression of
atheroma in patients with persistent proteinuria and hyperlip-
idemia, as suggested by a recent case-control study [6]. Lipid
lowering therapy may never be shown to reduce coronary heart
disease morbidity, mortality or total mortality in nephrotic
patients, given the very large trials needed to demonstrate a
beneficial effect [161.
It has been hypothesized that hyperlipidemia may itself
accelerate the progression of chronic renal disease by a variety
of mechanisms [7]. In addition, the pathophysiological pro-
cesses seen in focal glomerulosclerosis may in part parallel
those in atherosclerosis [17, 18]. Studies in the rat have pro-
vided evidence that hyperlipidemia accelerates the progression
of chronic glomerular disease, and conversely that its early
therapy slows the progression of renal injury [191.
Recently there has been interest in the treatment of hyper-
lipidemic proteinuric patients with lipid lowering therapy.
Study of such therapy has been difficult due to a lack of potent
lipid lowering agents, and side effects induced by these agents
(such as myositis induced by clofibrate [20]). The HMG CoA
reductase inhibitors have proved to be powerful cholesterol-
lowering agents with few side effects [8, 21], with the potential
to largely correct the severe hypercholesterolemia of the ne-
phrotic syndrome. There have been a number of small open
trials of the use of HMG CoA reductase inhibitors to treat
hypercholesterolemia in proteinuric patients [22—26]. One was a
crossover study [22] and four were essentially uncontrolled
[23—26]. All but one [26] used active therapy for three months or
less. We have carried out a double-blind, randomized, placebo
controlled trial of simvastatin therapy in hypercholesterolemic
patients with proteinuria or the nephrotic syndrome.
The thirty patients studied as a group had good renal func-
tion, heavy proteinuria and marked hypercholesterolemia, the
majority having a histological diagnosis of membranous glomer-
ulonephritis or focal glomerulosclerosis (Table 1). Simvastatin
therapy produced a rapid mean fall in total cholesterol of 30%,
LDL cholesterol of 31%, and a mean 25% fall in Apo B100
levels. Titration of drug dosage produced a modest further fall
in total cholesterol, LDL cholesterol and Apo B100 levels to
Time, weeks
Fig. 3. Urinary protein excretion of(•) simvastatin and (x) placebo.
Values shown are means with standard deviation bars.
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33%, 31% and 31% (respectively) below baseline levels at week
24. Ten milligrams of simvastatin produced most of the choles-
terol lowering effect. Many patients will respond satisfactorily
to this dose. However, some patients will require escalation to
maximal dose plus a second agent to reach target cholesterol
levels. It is important to note that the placebo treated patients,
despite continuing a supervised lipid lowering diet, only showed
a mean fall of 5% in their total cholesterol levels, a mean 1% rise
in LDL cholesterol and a mean 0.3% rise in Apo Bl0O levels.
The uncontrolled trials of high-dose HMG CoA reductase
inhibitor therapy in nephrosis generally showed slightly larger
percentage reductions in total and LDL cholesterol levels (31 to
37% and 39 to 45%, respectively). The differences may reflect
our use of the parallel group trial, with a placebo group
continuing on a lipid lowering diet. There was no significant
difference between the two groups in HDL cholesterol levels,
with wide confidence intervals for the difference between
groups in HDL changes. In primary hypercholesterolemia
HMG CoA reductase inhibitor therapy produces a dose-depen-
dent increase in HDL cholesterol levels, of up to 9.5% with a
comparable dose of lovastatin [271. There is marked between-
patient variability in the observed HDL changes [271. Three of
the five prior studies of HMG CoA reductase inhibitor therapy
in glomerulonephritis showed similar increases of about 10% in
HDL levels [24—26]. One study found changes similar to those
reported here [23]. None of the five studies showed a significant
change in HDL levels [22—26]. The differences between the
studies are probably due to high between-patient variability and
small sample size. Overall, our results and those of the other
trials are consistent with HMG CoA reductase inhibitor therapy
producing a small (5 to 10%) mean rise in HDL levels.
Trials of the HMG CoA reductase inhibitors have shown a
modest increase in the incidence of gastrointestinal complaints
and raised transaminase levels among those treated with active
therapy [21, 27]. Rare cases of myopathy have been associated
with cyclosporine, gemfibrozil, or niacin therapy [21]. In our
proteinuric patients simvastatin was well tolerated. Adverse
events were comparable in both groups. In particular there
were no cases of significant increases in transaminase or
creatine kinase levels, or overt hepatic or muscle dysfunction.
There was an increase in proteinuria among the simvastatin
treated patients and a decrease in proteinuria in the placebo
treated group. Simvastatin has been reported to be associated
with proteinuria in patients with primary hyperlipidemia in a
disputed case report [28, 29]. However, the mean changes in
proteinuria from weeks 0 to 24 were relatively small and not
significantly different between groups. In addition, in spite of
our stratification for proteinuria, the majority of the divergence
in proteinuria levels occurred during the placebo run-in phase
(Fig. 3). Our results do not suggest that simvastatin therapy
increases the remission rate in membranous glomerulonephri-
tis, a possibility raised by the uncontrolled data of Rabelink et
a! [30].
Simvastatin did not show any significant effects on renal
function during the six month trial. Creatinine increased and
inulin clearance decreased similarly in both groups. Among the
17 patients in whom complete data were available, inulin
clearance tended to decrease at a slower rate among simvastatin
treated patients compared with placebo treated patients, but the
difference was not significant. In their six-month uncontrolled
trial of lovastatin therapy for nephrotic hyperlipidemia Chan et
al found that lovastatin had a beneficial effect on GFR in a
subgroup with well-preserved renal function [26].
This trial is essentially a pilot study for a future, much larger
trial of longer-term lipid-lowering therapy in glomerular dis-
ease. Several factors make demonstration of a beneficial effect
of lipid lowering therapy on renal function in proteinuric
glomerular disease difficult. To use the analogy with atheroscle-
rosis, trials of lipid lowering therapy in primary hyperlipidemia
have only shown a reduction in mortality due to coronary heart
disease after two years of therapy [31, 32]. The levels to which
total and LDL cholesterol should be lowered for maximum
benefit in glomerular disease are unknown. In trials studying
"regression" of coronary atherosclerosis, the predominant
effect of lipid lowering therapy is the arresting of progression.
The maximum effect of therapy may be seen with a reduction on
treatment of total cholesterol to below 5 mmol/liter and LDL
cholesterol to about 2.5 mmol/liter [33]. The simvastatin treated
patients in our trial achieved total and LDL cholesterol levels of
about 6 and 3 mmollliter, respectively, on high doses of this
monotherapy. The marked variability in the rate of GFR decline
in patients with chronic renal disease means that a large trial is
needed to demonstrate whether potent lipid-lowering therapy
slows the rate of fall of GFR. Our data suggest what even a
three year trial aiming to detect a 30% reduction in the rate of
GFR decline (mean decline on placebo 25 mI/mm/i .73 m2,
standard deviation 20 mllmin/l.73 m2, 5% significance level,
90% power) would require about 150 patients completing fol-
low-up per group [34]. The required sample size is further
increased by a slower rate of progression, and by dropouts. The
experience from a two-year low protein diet trial [35], a 48 week
trial of lovastatin in primary hyperlipidemia [27], and our trial
suggest a withdrawal rate of 25% or more over three years.
In conclusion, in a double-blind, placebo controlled trial in 30
hypercholesterolemic proteinuric patients we have shown that
simvastatin safely and effectively lowers total and LDL choles-
terol levels by about 30%. In contrast a supervised "conven-
tional" lipid lowering diet alone produced only minor reduc-
tions in the levels of these lipoproteins. Over the six month
period of the trial there were no significant differences in
creatinine levels, urinary protein excretion or inulin clearance
between the simvastatin and placebo groups. It is possible that
lipid lowering therapy could slow the progression of renal
disease in hyperlipidemic, chronically proteinuric states. This
will not be easy to demonstrate in humans given the relative
rarity of patients eligible for clinical trials. Future studies
should be much larger multicenter trials. They will need to
study potent combinations of lipid lowering agents (such as an
HMG CoA reductase inhibitor and bile acid sequestrant [8])
over a prolonged period.
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